Clopidogrel Bisulfate
Product Images NDC 50090-1300

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 50090-1300). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500901300)

This is a product description for Clopidogrel Bisulfate tablets. The product has a product number of 6327-0 and contains 75mg of Clopidogrel Bisulfate. It is recommended to store the tablets at 87°F or under. The product comes with 30 tablets.*

FDA Label Image

Spl-clopidogrel-chemical-structure (Spl Clopidogrel Chemical Structure)

FDA Label Image

Spl-clopidogrel-fig-7 (Spl Clopidogrel Fig 7)

The text provides a figure showing the incidence of fatal or non-fatal vascular events in the CAPRIE study, comparing the use of aspirin versus clopidogrel. It includes a cumulative event rate (%) graph with months of follow-up on the x-axis and the percentage of events on the y-axis.*

FDA Label Image

Spl-clopidogrel-fig-8 (Spl Clopidogrel Fig 8)

FDA Label Image

Spl-clopidogrel-figure1 (Spl Clopidogrel Figure1)

This is a figure showing the effect of coadministered proton pump inhibitors (PPIs) on the exposure to the active metabolite of the drug Clopidogrel. The figure includes a graph with the mean and 90% confidence intervals for the effect of Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole on the active metabolite area under the curve (AUC) relative to administering Clopidogrel alone.*

FDA Label Image

Spl-clopidogrel-figure2 (Spl Clopidogrel Figure2)

The text describes Figure 2 of the CURE study, which shows the cumulative event rate of cardiovascular death, myocardial infarction, and stroke in patients receiving placebo or clopidogrel, both of which were taken with aspirin. The figure displays the event rate over 12 months of follow-up, and other standard therapies were used when appropriate.*

FDA Label Image

Spl-clopidogrel-figure3 (Spl Clopidogrel Figure3)

FDA Label Image

Spl-clopidogrel-figure4 (Spl Clopidogrel Figure4)

The text describes the COMMIT study and provides a graph showing the cumulative event rates for death before discharge among patients receiving either placebo or clopidogrel. The graph suggests that clopidogrel was associated with a lower risk of death, with a 7% proportional risk reduction compared to placebo (p=0.03). All patients received aspirin.*

FDA Label Image

Spl-clopidogrel-figure5 (Spl Clopidogrel Figure5)

The figure shows the cumulative event rates for a combined endpoint (reinfarction, stroke, or death) in patients within 28 days after randomization. The study, known as COMMIT, involved patients who had suffered a heart attack and all received aspirin. The placebo group had 10.1% of 2,310 patients experiencing the combined endpoint while the clopidogrel group had 9.2% of 2,121 patients experiencing it. The proportional risk reduction for clopidogrel versus placebo was 9% (p=0.002). Days since randomization are shown on the X-axis.*

FDA Label Image

Spl-clopidogrel-figure6 (Spl Clopidogrel Figure6)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.